Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib
详细信息 查看全文
- 作者：Ying Chen ; Brian I. Rini ; Robert J. Motzer ; Janice P. Dutcher…
- 刊名：Targeted Oncology
- 出版年：2016
- 出版时间：April 2016
- 年：2016
- 卷：11
- 期：2
- 页码：229-234
- 全文大小：425 KB
- 参考文献：1.Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, Chen JH, Rewolinski DA, Yamazaki S, Wu EY, McTigue MA, Murray BW, Kania RS, O'Connor P, Shalinsky DR, Bender SL (2008) Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 14:7272–7283. doi:10.1158/1078-0432.CCR-08-0652 CrossRef PubMed
2.Cohen RB, Oudard S (2012) Antiangiogenic therapy for advanced renal cell carcinoma: management of treatment-related toxicities. Invest New Drugs 30:2066–2079. doi:10.1007/s10637-012-9796-8 CrossRef PubMed PubMedCentral
3.Kelly RJ, Billemont B, Rixe O (2009) Renal toxicity of targeted therapies. Target Oncol 4:121–133. doi:10.1007/s11523-009-0109-x CrossRef PubMed
4.Izzedine H, Massard C, Spano JP, Goldwasser F, Khayat D, Soria JC (2010) VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management. Eur J Cancer 46:439–448. doi:10.1016/j.ejca.2009.11.001 CrossRef PubMed
5.Usui J, Glezerman IG, Salvatore SP, Chandran CB, Flombaum CD, Seshan SV (2014) Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature. Hum Pathol 45:1918–1927. doi:10.1016/j.humpath.2014.05.015 CrossRef PubMed
6.Patson B, R BC, Olszanski AJ (2012) Pharmacokinetic evaluation of axitinib. Expert Opin Drug Metab Toxicol 8:259-270. doi:10.1517/17425255.2012.652947
7.Chen Y, Tortorici MA, Garrett M, Hee B, Klamerus KJ, Pithavala YK (2013) Clinical pharmacology of axitinib. Clin Pharmacokinet 52:713–725. doi:10.1007/s40262-013-0068-3 CrossRef PubMed
8.Tortorici MA, Toh M, Rahavendran SV, Labadie RR, Alvey CW, Marbury T, Fuentes E, Green M, Ni G, Hee B, Pithavala YK (2011) Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics. Invest New Drugs 29:1370–1380. doi:10.1007/s10637-010-9477-4 CrossRef PubMed PubMedCentral
9.Pfizer Laboratories (2012) Inlyta® (axitinib) prescribing information. Pfizer Inc. http://labeling.pfizer.com/ShowLabeling.aspx?id=759 . Accessed 10 April 2015
10.Smith BJ, Pithavala Y, Bu HZ, Kang P, Hee B, Deese AJ, Pool WF, Klamerus KJ, Wu EY, Dalvie DK (2014) Pharmacokinetics, metabolism, and excretion of [14C]axitinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in humans. Drug Metab Dispos 42:918–931. doi:10.1124/dmd.113.056531 CrossRef PubMed
11.Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, Pithavala YK, Reich SD, Freddo JL, Wilding G (2005) Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 23:5474–5483. doi:10.1200/JCO.2005.04.192 CrossRef PubMed
12.Nolin TD, Naud J, Leblond FA, Pichette V (2008) Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clin Pharmacol Ther 83:898–903. doi:10.1038/clpt.2008.59 CrossRef PubMed
13.Rini BI, Garrett M, Poland B, Dutcher JP, Rixe O, Wilding G, Stadler WM, Pithavala YK, Kim S, Tarazi J, Motzer RJ (2013) Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis. J Clin Pharmacol 53:491–504. doi:10.1002/jcph.73 CrossRef PubMed PubMedCentral
14.Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou YC, Castellano D, Lim HY, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S, Motzer RJ (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378:1931–1939. doi:10.1016/S0140-6736(11)61613-9 CrossRef PubMed
15.Rixe O, Bukowski RM, Michaelson MD, Wilding G, Hudes GR, Bolte O, Motzer RJ, Bycott P, Liau KF, Freddo J, Trask PC, Kim S, Rini BI (2007) Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 8:975–984. doi:10.1016/S1470-2045(07)70285-1 CrossRef PubMed
16.Tomita Y, Uemura H, Fujimoto H, Kanayama HO, Shinohara N, Nakazawa H, Imai K, Umeyama Y, Ozono S, Naito S, Akaza H (2011) Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma. Eur J Cancer 47:2592–2602. doi:10.1016/j.ejca.2011.07.014 CrossRef PubMed
17.Rini BI, Wilding G, Hudes G, Stadler WM, Kim S, Tarazi J, Rosbrook B, Trask PC, Wood L, Dutcher JP (2009) Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 27:4462–4468. doi:10.1200/JCO.2008.21.7034 CrossRef PubMed
18.Huang SM, Temple R, Xiao S, Zhang L, Lesko LJ (2009) When to conduct a renal impairment study during drug development: US Food and Drug Administration perspective. Clin Pharmacol Ther 86:475–479. doi:10.1038/clpt.2009.190 CrossRef PubMed
19.Xu XS, Yuan M, Karlsson MO, Dunne A, Nandy P, Vermeulen A (2012) Shrinkage in nonlinear mixed-effects population models: quantification, influencing factors, and impact. AAPS J 14:927–936. doi:10.1208/s12248-012-9407-9 CrossRef PubMed PubMedCentral
20.Savic RM, Karlsson MO (2009) Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J 11:558–569. doi:10.1208/s12248-009-9133-0 CrossRef PubMed PubMedCentral
21.Committee for Medicinal Products for Human Use (CHMP) (2004) Note for guidance on the evaluation of the pharmacokinetics of medicinal products in patients with impaired renal function. European Medicines Agency. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003123.pdf . Accessed 10 April 2015
22.Khosravan R, Toh M, Garrett M, La Fargue J, Ni G, Marbury TC, Swan SK, Lunde NM, Bello CL (2010) Pharmacokinetics and safety of sunitinib malate in subjects with impaired renal function. J Clin Pharmacol 50:472–481. doi:10.1177/0091270009347868pan> CrossRef PubMed
23.Smith W, Marbury T, Kipnes M, Cihon F, Lettieri J, Mazzu A (2007) Effects of renal impairment on the pharmacokinetics of sorafenib and its metabolites. Cancer Res 67:934
24.Gupta S, Parsa V, Heilbrun LK, Smith DW, Dickow B, Heath E, Vaishampayan U (2011) Safety and efficacy of molecularly targeted agents in patients with metastatic kidney cancer with renal dysfunction. Anticancer Drugs 22:794–800. doi:10.1097/CAD.0b013e328346af0dpan> CrossRef PubMed PubMedCentral
25.Kim KH, Kim HY, Kim HR, Sun JM, Lim HY, Lee HJ, Lee S, Bae WK, Rha SY (2014) Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency. Eur J Cancer 50:746–752. doi:10.1016/j.ejca.2013.11.029 CrossRef PubMed
26.Josephs D, Hutson TE, Cowey CL, Pickering LM, Larkin JM, Gore ME, Van Hemelrijck M, McDermott DF, Powles T, Chowdhury P, Karapetis C, Harper PG, Choueiri TK, Chowdhury S (2011) Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis. BJU Int 108:1279–1283. doi:10.1111/j.1464-410X.2010.09990.x CrossRef PubMed
27.Shetty AV, Matrana MR, Atkinson BJ, Flaherty AL, Jonasch E, Tannir NM (2014) Outcomes of patients with metastatic renal cell carcinoma and end-stage renal disease receiving dialysis and targeted therapies: a single institution experience. Clin Genitourin Cancer 12:348–353. doi:10.1016/j.clgc.2014.01.004 CrossRef PubMed PubMedCentral
28.Masini C, Sabbatini R, Porta C, Procopio G, Di Lorenzo G, Onofri A, Buti S, Iacovelli R, Invernizzi R, Moscetti L, Aste MG, Pagano M, Grosso F, Lucia Manenti A, Ortega C, Cosmai L, Del Giovane C, Conte PF (2012) Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey. BJU Int 110:692–698. doi:10.1111/j.1464-410X.2012.10946.x CrossRef PubMed
29.SUTENT® (sunitinib malate) prescribing information (2014). Pfizer Inc, New York, NY, USA
30.VOTRIENT (pazopanib) prescribing information (2014). GlaxoSmithKline, Research Triangle Park, NC, USA - 作者单位：Ying Chen (1)
Brian I. Rini (2)
Robert J. Motzer (3)
Janice P. Dutcher (4)
Olivier Rixe (5)
George Wilding (6)
Walter M. Stadler (7)
Jamal Tarazi (1)
May Garrett (1)
Yazdi K. Pithavala (1) (8)
1. Pfizer Oncology, San Diego, CA, USA
2. Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA
3. Memorial Sloan Kettering Cancer Center, New York, NY, USA
4. New York Medical College, Valhalla, NY, USA
5. University of New Mexico Cancer Center, Albuquerque, NM, USA
6. University of Wisconsin Carbone Comprehensive Cancer Center, Madison, WI, USA
7. Department of Medicine, University of Chicago, Chicago, IL, USA
8. Clinical Pharmacology, Pfizer Inc, 10555 Science Center Drive, San Diego, CA, 92121, USA - 刊物主题：Oncology; Biomedicine general;
- 出版者：Springer Paris
- ISSN：1776-260X
文摘
Background Axitinib, an inhibitor of vascular endothelial growth factor (VEGF) receptors, is approved as second-line treatment for advanced renal cell carcinoma (RCC). Agents targeting the VEGF pathway may induce renal toxicities, which may be influenced by pre-existing renal dysfunction.